JP7854389B2 - Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物 - Google Patents

Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物

Info

Publication number
JP7854389B2
JP7854389B2 JP2022520290A JP2022520290A JP7854389B2 JP 7854389 B2 JP7854389 B2 JP 7854389B2 JP 2022520290 A JP2022520290 A JP 2022520290A JP 2022520290 A JP2022520290 A JP 2022520290A JP 7854389 B2 JP7854389 B2 JP 7854389B2
Authority
JP
Japan
Prior art keywords
compound
chemical formula
pharmaceutically acceptable
skin
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022520290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551583A (ja
JP2022551583A5 (https=
Inventor
ベッツ アンドレアス
ザンボーニ ロバート
Original Assignee
モレキュラー スキン セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー スキン セラピューティクス，インコーポレイティド filed Critical モレキュラー スキン セラピューティクス，インコーポレイティド
Publication of JP2022551583A publication Critical patent/JP2022551583A/ja
Publication of JP2022551583A5 publication Critical patent/JP2022551583A5/ja
Application granted granted Critical
Publication of JP7854389B2 publication Critical patent/JP7854389B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022520290A 2019-10-01 2020-09-30 Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物 Active JP7854389B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909006P 2019-10-01 2019-10-01
US62/909,006 2019-10-01
PCT/US2020/053369 WO2021067335A1 (en) 2019-10-01 2020-09-30 Benzoxazinone compounds as klk5/7 dual inhibitors

Publications (3)

Publication Number Publication Date
JP2022551583A JP2022551583A (ja) 2022-12-12
JP2022551583A5 JP2022551583A5 (https=) 2023-09-29
JP7854389B2 true JP7854389B2 (ja) 2026-05-01

Family

ID=75274622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520290A Active JP7854389B2 (ja) 2019-10-01 2020-09-30 Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物

Country Status (12)

Country Link
US (2) US11643420B2 (https=)
EP (1) EP4037687B1 (https=)
JP (1) JP7854389B2 (https=)
KR (1) KR20220091488A (https=)
CN (1) CN114615984B (https=)
AU (1) AU2020359526A1 (https=)
BR (1) BR112022005881A2 (https=)
CA (1) CA3151626A1 (https=)
ES (1) ES3053975T3 (https=)
IL (1) IL291398B2 (https=)
MX (1) MX2022003929A (https=)
WO (1) WO2021067335A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
PH12022550646A1 (en) 2019-09-18 2023-04-03 Genentech Inc Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
ES3053975T3 (en) 2019-10-01 2026-01-28 Molecular Skin Therapeutics Inc Benzoxazinone compounds as klk5/7 dual inhibitors
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009790A1 (fr) 1987-06-09 1988-12-15 Teijin Limited Composes de 4h-3,1-benzoxazin-4-one et composition medicinale inhibant la serine protease contenant lesdits composes
WO1993008254A1 (de) 1991-10-22 1993-04-29 Basf Aktiengesellschaft Körnige bleichaktivatorzusammensetzung
JP2006526581A (ja) 2003-06-06 2006-11-24 アレクシス・アクチボラゲット 皮膚状態または癌の処置のためのｓｃｃｅ阻害剤としての縮合複素環化合物の使用
JP2017503798A (ja) 2014-01-23 2017-02-02 シクセラ ファーマ エービー 皮膚病の処置のためのベンゾオキサジノン誘導体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2184851A1 (en) 1996-09-05 1998-03-06 Cheng Chung Wu Method of manufacturing a microweavable flatware article made of synthetic material, the article produced thereby and an ink-imprinted film component for use in making the flatware article
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
PL343317A1 (en) * 1998-03-31 2001-08-13 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES3053975T3 (en) 2019-10-01 2026-01-28 Molecular Skin Therapeutics Inc Benzoxazinone compounds as klk5/7 dual inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009790A1 (fr) 1987-06-09 1988-12-15 Teijin Limited Composes de 4h-3,1-benzoxazin-4-one et composition medicinale inhibant la serine protease contenant lesdits composes
WO1993008254A1 (de) 1991-10-22 1993-04-29 Basf Aktiengesellschaft Körnige bleichaktivatorzusammensetzung
JP2006526581A (ja) 2003-06-06 2006-11-24 アレクシス・アクチボラゲット 皮膚状態または癌の処置のためのｓｃｃｅ阻害剤としての縮合複素環化合物の使用
JP2017503798A (ja) 2014-01-23 2017-02-02 シクセラ ファーマ エービー 皮膚病の処置のためのベンゾオキサジノン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
4-(6,7-dimethoxy-4-oxo-4H-3,1-benzoxazin-2-yl)phenyl propanoate，PubChem，PubChem CID 2993515 Create : 2005-07-29
Tomasz Kantyka et al.，Inhibition of kallikrein-related peptidases by the serineprotease inhibitor of Kazal-type 6，Peptides，Volume 32, Issue 6，2011年，pp.1187-1192，DOI: 10.1016/j.peptides.2011.03.009

Also Published As

Publication number Publication date
BR112022005881A2 (pt) 2022-06-21
CN114615984A (zh) 2022-06-10
TW202126631A (zh) 2021-07-16
US12281123B2 (en) 2025-04-22
IL291398B1 (en) 2025-01-01
ES3053975T3 (en) 2026-01-28
JP2022551583A (ja) 2022-12-12
AU2020359526A1 (en) 2022-04-21
IL291398A (en) 2022-05-01
US20210101911A1 (en) 2021-04-08
IL291398B2 (en) 2025-05-01
EP4037687B1 (en) 2025-10-29
MX2022003929A (es) 2022-06-14
WO2021067335A1 (en) 2021-04-08
CN114615984B (zh) 2025-02-07
CA3151626A1 (en) 2021-04-08
EP4037687A4 (en) 2023-09-27
EP4037687A1 (en) 2022-08-10
US20240067658A1 (en) 2024-02-29
US11643420B2 (en) 2023-05-09
KR20220091488A (ko) 2022-06-30

Similar Documents

Publication Publication Date Title
JP7854389B2 (ja) Ｋｌｋ５／７デュアル阻害剤としてのベンゾキサジノン化合物
CN111065393B (zh) 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物
KR101236166B1 (ko) 네비볼롤을 함유하는 조성물
EP3019166B1 (en) A pharmaceutical combination for the treatment of melanoma
AU2020324435B2 (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EP2069377A2 (en) Methods and compositions for the treatment of skin diseases and disorders
JP2023520462A (ja) フリードライヒ運動失調症を含むミトコンドリア病の予防および／または治療のための組成物および方法
JP2021535087A (ja) リシルオキシダーゼのハロアリルアミンスルホン誘導体阻害剤およびそれらの使用
JP2020520994A (ja) 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
CN113473986B (zh) 用于治疗皮肤疾病萘啶酮苯胺化合物
EP1277743A1 (en) Oxa(thia)zolidine derivative and anti-inflammatory drug
HK1200815A1 (en) [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors
RU2831430C1 (ru) Соединения бензоксазинона в качестве двойных ингибиторов klk5/7
TWI918610B (zh) 作為ｋｌｋ５/７雙重抑制劑之苯并酮化合物
Yamamoto et al. Inhibitory effect of a potent and selective cytosolic phospholipase A2α inhibitor RSC-3388 on skin inflammation in mice
KR20250004665A (ko) 비장 티로신 키나아제 억제제, 조성물 및 사용 방법
HK40118407A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
US11608320B2 (en) Oxazolidinone hydroxamic acid derivatives
HK40075560B (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
HK40075560A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
EA052521B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
EA048135B1 (ru) Применение сепиаптерина и его метаболитов для лечения радиационного облучения
HK1224936A1 (en) A pharmaceutical combination for the treatment of melanoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260420